tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Telix Pharmaceuticals Ltd

TLX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
9.910USD
-0.150-1.49%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
0.00์‹œ๊ฐ€์ด์•ก
--P/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ์ฐจํŠธ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-1.49%

5์ผ

-3.03%

1๊ฐœ์›”

-16.30%

6๊ฐœ์›”

+36.13%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+32.31%

1๋…„

-27.08%

ํ•ต์‹ฌ ์ˆ˜์น˜
10.000์‹œ๊ฐ€
10.012์ตœ๊ณ ๊ฐ€
80.93K๊ฑฐ๋ž˜๋Ÿ‰
--P/E TTM
0.00๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
--ํšŒ์ „์œจ
10.060์ „์ผ ์ข…๊ฐ€
9.790์ตœ์ €๊ฐ€
612.50K๋งค์ถœ์•ก
--์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
--P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
--ROA
18.49052์ฃผ ์ตœ๊ณ ๊ฐ€
1.02๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
--์ˆœ์ด์ต
--์ฃผ์‹
--์ฃผ๋‹น์ˆœ์ด์ต
--๋ฒ ํƒ€
--ROE
6.28052์ฃผ ์ตœ์ €๊ฐ€
2.21%๋ณ€๋™ ํญ
--์ด ์ด์ต๋ฅ 
0.00์‹œ๊ฐ€์ด์•ก
-8.69๋ณด์ƒ/์œ„ํ—˜
1.75%์œ„ํ—˜๋ฅ 

Telix Pharmaceuticals Ltd ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์˜ˆ์ƒ๎˜

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

5 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๊ฐ•๋ ฅ ๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
19.291
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+91.00%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

496
์ด๊ณ„
6
์ค‘๊ฐ„
7
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
Telix Pharmaceuticals Ltd
TLX
5
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

์ง€ํ‘œ๎˜

์ง€ํ‘œ
๋งค๋„(4)
์ค‘๋ฆฝ(1)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.277
๋งค๋„
RSI(14)
40.103
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
13.030
๊ณผ๋งค์ˆ˜
ATR(14)
0.354
๊ณ ๋ณ€๋™์„ฑ
CCI(14)
-113.744
๋งค๋„
Williams %R
93.333
๊ณผ๋งค์ˆ˜
TRIX(12,20)
-0.231
๋งค๋„
StochRSI(14)
0.000
๋งค๋„
์ด๋™ ํ‰๊ท 
๋งค๋„(5)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(1)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
10.044
๋งค๋„
MA10
10.270
๋งค๋„
MA20
10.781
๋งค๋„
MA50
10.310
๋งค๋„
MA100
10.074
๋งค๋„
MA200
9.305
๋งค์ˆ˜

Telix Pharmaceuticals Ltd ์ •๋ณด๎˜

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
์ข…๋ชฉ ์ฝ”๋“œ TLX
ํšŒ์‚ฌTelix Pharmaceuticals Ltd
CEOOrtiz (Raphaeel)
์›น์‚ฌ์ดํŠธhttps://telixpharma.com/

์ฃผ์ฃผ๎˜

์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
๊ธฐํƒ€
99.76%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Telix Pharmaceuticals Ltd(TLX)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Telix Pharmaceuticals Ltd(TLX)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 9.91์ž…๋‹ˆ๋‹ค.

Telix Pharmaceuticals Ltd์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Telix Pharmaceuticals Ltd์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” TLX์ž…๋‹ˆ๋‹ค.

Telix Pharmaceuticals Ltd์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Telix Pharmaceuticals Ltd์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 18.49์ž…๋‹ˆ๋‹ค.

Telix Pharmaceuticals Ltd์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Telix Pharmaceuticals Ltd์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 6.28์ž…๋‹ˆ๋‹ค.

Telix Pharmaceuticals Ltd(TLX)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, Telix Pharmaceuticals Ltd(TLX)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ STRONG BUY ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 19.29์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ